Biofidelity
The fast-growth firm, which has operations in Cambridge, UK and North Carolina, US, recently raised $24 million to speed up commercial and clinical expansion in the US to accelerate the adoption of ASPYRE®-Lung, a novel test that dramatically simplifies and accelerates the detection of biomarkers for non-small cell lung cancer.
The latest funding takes its haul to $60m since launch. Investors include Agilent Technologies, Octopus Ventures, BlueYard Capital, and Longwall Ventures.
Led by CEO and co-founder, Dr Barnaby Balmforth, Biofidelity’s technology is a groundbreaking new approach to genomic analysis. By removing the noise of uninformative DNA — thus eliminating a crucial existing barrier to analysis — its products can significantly and cost-effectively reduce the complexity of analysis and improve speed and accuracy to facilitate faster decision-making.
The company says its technology enables clinicians to determine which treatment is best for each patient in days instead of weeks at a fraction of the cost of current sequencing tests.
